VolitionRx Limited Releases Video of Virtual Capital Markets Day 2020
AUSTIN, Texas, Oct. 21, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, hosted a capital ma...
VolitionRx Limited Announces Details for Virtual Capital Markets Day 2020
AUSTIN, Texas, Oct. 20, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, will host a capital...
Volition Veterinary Diagnostics Development LLC Announces Product Data Regarding its Nu.Q™ Vet Cancer Screening Test in Lymphoma and Hemangiosarcoma to be Presented at the 2020 VCS Virtual Annual Conference
* Positive data show high sensitivity and specificity in the detection of Lymphoma and Hemangiosarcoma as Volition remains on target for launch of its first product expected later this year * Cancer is the most common cause of death in dogs over the age of two years old in the U.S. * Togeth...
VolitionRx Limited Announces Details for Virtual Capital Markets Day 2020
AUSTIN, Texas, Oct. 14, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, announced further d...
Volition Veterinary Diagnostics Development LLC to Present Product Data Regarding its Nu.Q™ Vet Cancer Screening Test at the 2020 VCS Virtual Annual Conference
AUSTIN, Oct. 12, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, will present two abstract...
VolitionRx Limited Announces Virtual Capital Markets Day 2020
AUSTIN, Texas, Sept. 29, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases, today announced it will host a capital market...
VolitionRx Limited to Present at Conferences in September 2020
AUSTIN, Texas, Sept. 1, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that its Chief Executive Officer,Cameron Reynolds, and its Executive Vice President, Investor Relations, Scott Powell, are scheduled to present at five conferences inSeptember 2020. ...
VolitionRx Limited Announces Second Quarter 2020 Financial Results and Business Update
AUSTIN, Texas, August 13, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the second quarter endedJune 30, 2020. Volition management will host a conference call tomorrow,August 14 at 8:30 a.m. U.S. Eastern Time...
VolitionRx Limited Schedules Second Quarter 2020 Earnings Conference Call and Business Update
AUSTIN, Texas, Aug. 10, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call onFriday, August 14, at 8:30 a.m. Eastern time to discuss its financial and operating results for the second quarter 2020, in addition to providing a b...
Volition Announces Promising Clinical Trials Results for its Novel COVID-19 Triage Test
AUSTIN, Texas, July 14, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company applying its Nu.Q™ Nucleosomics™ technology to develop simple, cost effective blood-based tests for cancer and other diseases, today announced that results from...
VolitionRx Releases Business Update Video and Announces Addition to the Russell 3000® and Russell Microcap® Indexes
AUSTIN, Texas, June 25, 2020 /PRNewswire/ -- VolitionRx Limited
Volition Announces Cameron Reynolds, President and Chief Executive Officer Invited as Presenter at Maxim's COVID-19 Virtual Conference
AUSTIN, May 27, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that President and Chief Executive Officer,Cameron Reynolds has been invited to present at The Role of Cell Therapy and Clarity on Testing Conference organised by the Maxim Group. Event Det...
VolitionRx Announces Closing of $13.8 Million Public Offering of Common Stock
AUSTIN, Texas, May 22, 2020 /PRNewswire/ -- VolitionRx Limited
VolitionRx Announces Pricing of Underwritten Public Offering of Common Stock
AUSTIN, Texas, May 20, 2020 /PRNewswire/ -- VolitionRx Limited
VolitionRx Announces Proposed Underwritten Public Offering of Common Stock
AUSTIN, Texas, May 19, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy to use, cost-effective blood tests to help diagnose a range of cancers a...
VolitionRx To Present First Data on Nu.Q™ Capture Performance and Nu.Q™ Assay Performance in Lung Cancer and Blood Cancer at the 2020 ASCO Annual Meeting
AUSTIN, Texas, May 13, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), an epigenetics company developing simple, easy to use and cost effective blood tests to help diagnose a range of cancers, will present three abstracts at the 2020 ASCO Annual Meeting. The first abs...
VolitionRx Limited Announces First Quarter 2020 Financial Results and Business Update
AUSTIN, Texas, May 7, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the first quarter endedMarch 31, 2020. Volition management will host a conference call tomorrow,May 8 at 8:30 a.m. U.S. Eastern Time to disc...
VolitionRx Limited Schedules First Quarter 2020 Earnings Conference Call and Business Update
AUSTIN, Texas, May 5, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call onFriday, May 8, at 8:30 a.m. Eastern time to discuss its financial and operating results for the first quarter 2020, in addition to providing a business...
Volition's Nu.Q™ Vet Assay Detects Two Common Canine Cancers
AUSTIN, Texas, April 29, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced results from its first proof of concept study conducted byTexas A&M University ("TAMU"). At a specificity of 90%, a single Nu.Q™ Vet assay detected almost 70% of both Canine Hemang...
Volition Files Patent for Nu.Q(TM) COVID-19 Triage Test and Commences Proof of Concept Studies
AUSTIN, Texas, April 23, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it is actively developing a COVID-19 triage test aiming to predict the likelihood that an individual who is COVID-19 positive will develop complications and severe disease, usi...
